Inflection Point VI’s New Nasdaq Symbols Are Out; $10.15 In Focus This Week

Inflection Point VI’s New Nasdaq Symbols Are Out; $10.15 In Focus This Week

May 24, 2026

New York, May 24, 2026, 09:03 EDT

Inflection Point Acquisition Corp. VI units (IPFXU) finished Friday at $10.15, trading just above their IPO price as the blank-check firm wrapped its first week on the market with separated shares and warrants. U.S. exchanges are closed for the weekend, and Nasdaq won’t open Monday for Memorial Day. Trading resumes Tuesday.

The timing is important now that investors can put a value on the three different parts: units trading under IPFXU, Class A shares under IPFX, and warrants under IPFXW. Each unit has a Class A share plus a third of a warrant. A warrant lets the holder buy a share later at a set price—the price here is $11.50 if you have a whole warrant.

SPACs, or special purpose acquisition companies, are shells that go public to raise funds and search for a private company to buy or merge with. Inflection Point VI fits that description. It’s not an operating company. Instead, it’s a pool of cash with eyes on the trust account, the pile of money that can be used for a deal or for shareholder redemptions.

Class A shares were last at $10.03, according to market data. Warrants traded at $0.655, up 1.5 cents, with volume at 29,659. The latest trade data showed just 53 shares trading. Early SPAC action can be spotty.

Index change cropped up too. MarketScreener showed IPFX shares from Inflection Point VI added to the Nasdaq Composite Index on May 18, which lined up with the planned start for separate trading. The Nasdaq Composite tracks broad Nasdaq-listed names.

Inflection Point VI finished its IPO in March, selling 25.3 million units at $10 apiece. The deal included the full over-allotment option from underwriters, raising $253 million in total gross proceeds. All $253 million went into trust, according to the company. It also raised $7.4 million from a private sale of 7.4 million warrants.

The company said it’s looking to combine with a North American or European target in “disruptive growth sectors,” but could go after any region or industry. Chairman Michael Blitzer leads the group, with Kevin Shannon as CEO and Adam Saks as CFO. GlobeNewswire

Inflection Point Acquisition Corp. V (IPEX) closed at $10.48, up a penny on the day and giving it a market cap of roughly $124.8 million. The move keeps both this and its peer vehicles trading close to the $10 line common among SPACs, where the focus is still on trust value, sponsor history and deal potential instead of numbers like revenue or profit.

But the trade is risky both ways. Inflection Point VI in its quarterly filing said it hasn’t started operating and won’t bring in revenue until it completes a business combination; it warned that if searching for and striking a deal eats up more cash than planned, it could end up short outside the trust. Warrants carry more risk, losing value quickly if no good target shows up or if a merger down the road needs new cash.

Outlook for the week is tight and focused: Tuesday’s trading restart matters, along with any change in the spread between the company and its spin-off parts, plus news from filings if they come in. No deal is on the table yet. Right now, it’s about whether the market sticks with a small premium above the $10 IPO price as the sponsor keeps hunting for an acquisition.

Stock Market Today

  • GSK Shares Rise on Orphan Drug Status and $10.6 Billion Nuvalent Oncology Deal
    June 12, 2026, 9:13 AM EDT. GSK shares rose 1.32% after momelotinib earned Orphan Drug Designation from the US FDA and European Medicines Agency for VEXAS syndrome, a rare inflammatory disorder. This designation offers development incentives but does not authorize sales. The boost follows GSK's $10.6 billion acquisition of Nuvalent, adding late-stage lung cancer drugs zidesamtinib and neladalkib, with FDA decisions due by November 2026. GSK posted 5% sales growth in Q1 2026, driven by Specialty Medicines up 14% and oncology up 28%. The company aims for 3%-5% turnover growth and 7%-9% profit rise in 2026 but faces patent expiry and integration risks from the Nuvalent deal. Investors focus on upcoming ATLAS trial data and regulatory milestones for pipeline momentum.